Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 19/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21200404 | 1.00 | CBLB (0.54) | CBLBTSHRMAPK1 | |
| SCHEMBL29867551 | 1.00 | CBLB (0.54) | CBLBTSHRMAPK1 | |
| SCHEMBL29626771 | 1.00 | CBLB (0.54) | CBLBTSHRMAPK1 | |
| SCHEMBL21200737 | 1.00 | CBLB (0.54) | CBLBTSHRMAPK1 | |
| SCHEMBL29626732 | 1.00 | CBLB (0.54) | CBLBTSHRMAPK1 | |
| SCHEMBL28741983 | 0.78 | CBLB (0.49) | CBLB | |
| SCHEMBL21200198 | 0.77 | CBLB (0.66) | CBLB | |
| SCHEMBL29841601 | 0.76 | CBLB (0.56) | CBLBTSHRMAPK1 | |
| SCHEMBL29841599 | 0.76 | CBLB (0.56) | CBLBTSHRMAPK1 | |
| SCHEMBL21201026 | 0.74 | CBLB (0.46) | CBLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | CBLB, CBL, CBLC | CBLB 1/4885TSHR 3909/4885MAPK1 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.